Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis.
about
Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human geneticsOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisHypoxia and Integrin-Mediated Epithelial Restitution during Mucosal InflammationTrefoil factors in inflammatory bowel diseaseIntestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing.Trefoil factor 3 as an endocrine neuroprotective factor from the liver in experimental cerebral ischemia/reperfusion injuryTrefoil Factor 3 (TFF3) Is Regulated by Food Intake, Improves Glucose Tolerance and Induces Mucinous Metaplasia.Evolving knowledge and therapy of inflammatory bowel disease.Epithelial restitution and wound healing in inflammatory bowel disease.Quantitative measurements of trefoil factor family peptides: possibilities and pitfalls.Intestinal barrier homeostasis in inflammatory bowel disease.Trans-system mechanisms against ischemic myocardial injury.Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis.Electrical, enzymatic graphene biosensing of 5-aminosalicylic acid.Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.
P2860
Q21131205-BF4CE352-32C5-4CB7-A788-8A9821C0499BQ24185876-65FFAB96-5DC7-48EE-8565-DE69CEA575E5Q24198024-F9CA4FA6-8201-40D3-91AF-20D285B52EC0Q24246220-56BC3EA6-21E7-4C10-9BC4-4673241251A5Q26995631-F692440F-B958-492F-9330-47F142565FC1Q27015771-E8E4FECD-ECB5-4E50-8B08-2EB6DE315138Q33694525-C0DD5233-03AA-4387-8134-EF9913571B21Q35035539-E1C74D3F-C946-4373-916F-F26BAB44E483Q35666227-6C648E60-91E4-45EF-A577-34D742C0C096Q36414506-29DE0E56-CBCF-402F-BABB-7778FB5ECC36Q37058859-B0DE6FF9-EF78-4F25-9C65-62F9B4428CC3Q38079874-793156B1-DD00-4BFB-BD97-5BF7E8678EE3Q38293757-E75FC2FA-A64F-45FD-91B9-E841AF443FAEQ38318626-A0CA6C56-B664-44E0-BBC1-D9058747479CQ38505808-BFF462CE-F690-4F0F-ABC9-A3EEE2A1570FQ44344227-F6A3613A-2590-4F05-923E-7C4B545CE97FQ46452033-67DF4EA3-855C-46B4-9A23-448198A6C550Q55439079-E862D009-18A7-464E-8624-50DED2C9C63F
P2860
Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Trial of trefoil factor 3 enem ...... left-sided ulcerative colitis.
@en
Trial of trefoil factor 3 enem ...... left-sided ulcerative colitis.
@nl
type
label
Trial of trefoil factor 3 enem ...... left-sided ulcerative colitis.
@en
Trial of trefoil factor 3 enem ...... left-sided ulcerative colitis.
@nl
prefLabel
Trial of trefoil factor 3 enem ...... left-sided ulcerative colitis.
@en
Trial of trefoil factor 3 enem ...... left-sided ulcerative colitis.
@nl
P2093
P2860
P1476
Trial of trefoil factor 3 enem ...... left-sided ulcerative colitis.
@en
P2093
A J Fitzgerald
R J Playford
P2860
P304
P356
10.1111/J.1365-2036.2005.02436.X
P407
P577
2005-06-01T00:00:00Z